Altimmune
ALT
2.59
-0.07
-2.63%
Altimmune
US · ALT
#3727 by market cap
2.59
-0.07
-2.63%
Live - 5344 symbols - heartbeat 286s ago
· 2026-10-08 10:00
Pre-market
2.66
0.00%
After-hours
2.67
+0.38%
Overnight
2.68
+0.75%
- Market cap
- 503.80M
- P/E (TTM)i
- -3.41
- P/Bi
- 1.06
- EPSi
- -1.00
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on ALT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.26, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +105.00% YoY
Margins
- Operating margin
- -230,460.98%
- Net margin
- -214,860.98%
Key ratios & quality
- Enterprise valuei
- 264.89M
- Altman Z-Scorei
- 2.26
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.33M | 5.80M | 8.19M | 4.41M | -68.00K | 426.00K | 20.00K | 41.00K |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.77M | 8.50M | 13.21M | 15.41M | 17.13M | 18.14M | 20.97M | 28.10M |
| Research & development | 18.46M | 17.77M | 49.77M | 74.54M | 70.54M | 65.80M | 82.23M | 66.43M |
| Operating profit | -17.89M | -20.46M | -54.80M | -85.54M | -87.74M | -83.51M | -103.17M | -94.49M |
| Pretax profit | -45.32M | -20.58M | -54.46M | -97.09M | -84.91M | -88.45M | -95.06M | -88.77M |
| Tax | -6.15M | -58.50K | -5.42M | 0 | -197.00K | -- | 0 | -681.00K |
| Net profit | -39.17M | -20.52M | -49.04M | -97.09M | -84.71M | -88.45M | -95.06M | -88.09M |
| Basic EPS | -15 | -2 | -2 | -2 | -2 | -2 | -1 | -1 |
| Diluted EPS | -15.16 | -1.60 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 5.00K | 5.00K | 5.00K | 26.00K | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.99M | 5.69M | 5.90M | 10.51M | 8.05M | 7.57M |
| Research & development | 15.83M | 17.24M | 14.96M | 18.41M | 16.19M | 18.66M |
| Operating profit | -21.82M | -22.92M | -20.86M | -28.89M | -24.24M | -26.23M |
| Pretax profit | -20.26M | -22.15M | -19.01M | -27.36M | -22.56M | -22.83M |
| Tax | -681.00K | 0 | 0 | 0 | 0 | 0 |
| Net profit | -19.58M | -22.15M | -19.01M | -27.36M | -22.56M | -22.83M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.26 | -0.27 | -0.21 | -0.27 | -0.18 | -0.12 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 39.37M | 39.39M | 230.26M | 204.13M | 192.81M | 209.63M | 137.25M | 278.19M |
| Cash & ST investments | 33.72M | 37.24M | 215.92M | 190.30M | 184.88M | 197.82M | 131.89M | 273.46M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 54.75M | 54.06M | 245.12M | 218.87M | 206.93M | 210.64M | 139.31M | 279.93M |
| Total current liabilities | 4.53M | 3.92M | 12.02M | 18.28M | 17.05M | 12.14M | 10.47M | 15.00M |
| Short-term debt | 71.60K | 259.45K | 356.72K | 411.00K | 452.00K | 496.00K | 279.00K | 256.00K |
| Long-term debt | 501.17K | -- | -- | -- | -- | -- | -- | 34.29M |
| Total liabilities | 6,437,976.00 | 8,537,874.00 | 19,238,890.00 | 19,730,000.00 | 21,635,000.00 | 16,541,000.00 | 15,798,000.00 | 55,037,000.00 |
| Total equity | 48.31M | 45.52M | 225.88M | 199.14M | 185.29M | 194.10M | 123.51M | 224.89M |
| Retained earnings | -116.86M | -137.38M | -186.42M | -293.17M | -377.88M | -466.33M | -561.39M | -649.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 155.26M | 188.42M | 216.62M | 278.19M | 334.68M | 334.82M |
| Cash & ST investments | 149.83M | 183.11M | 210.78M | 273.46M | 331.54M | 326.28M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 157.26M | 190.35M | 218.45M | 279.93M | 335.63M | 527.21M |
| Total current liabilities | 9.80M | 9.22M | 12.61M | 15.00M | 11.32M | 12.50M |
| Short-term debt | 245.00K | 239.00K | 247.00K | 256.00K | 265.00K | 274.00K |
| Long-term debt | -- | 14.33M | 14.45M | 34.29M | 34.51M | 34.74M |
| Total liabilities | 15,101,000.00 | 28,983,000.00 | 32,846,000.00 | 55,037,000.00 | 51,643,000.00 | 53,004,000.00 |
| Total equity | 142.16M | 161.37M | 185.60M | 224.89M | 283.99M | 474.21M |
| Retained earnings | -580.97M | -603.11M | -622.13M | -649.48M | -672.05M | -694.87M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.39M | -9.60M | -34.31M | -78.24M | -62.59M | -75.81M | -79.85M | -67.54M |
| Depreciation & amortization | 302.37K | 387.32K | 428.88K | 551.00K | 493.00K | 477.00K | 238.00K | 112.00K |
| Free cash flow | -10.40M | -9.63M | -34.65M | -90.55M | -62.71M | -75.86M | -79.85M | -67.55M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 37.40M | 12.67M | 172.32M | 65.04M | 56.35M | 86.60M | 9.99M | 173.73M |
| Ending cash balance | 34.35M | 9.00M | 115.95M | 190.34M | 111.13M | 135.16M | 36.97M | 43.80M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -16.84M | -19.35M | -11.90M | -19.45M | -20.94M | -24.22M |
| Depreciation & amortization | 29.00K | 30.00K | 27.00K | 26.00K | 23.00K | 23.00K |
| Free cash flow | -16.84M | -19.36M | -11.90M | -19.45M | -20.96M | -24.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 34.92M | 37.36M | 40.11M | 61.35M | 79.26M | 210.80M |
| Ending cash balance | 49.15M | 183.15M | 61.28M | 43.80M | 97.64M | 63.05M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -96.86 | -44.70 | -36.14 | -45.69 | -44.07 | -46.63 | -59.86 | -50.57 |
| ROA %i | -72.13 | -38.55 | -32.79 | -41.85 | -39.79 | -42.36 | -54.33 | -42.03 |
| ROIC %i | -95.40 | -45.37 | -35.88 | -45.42 | -45.24 | -50.24 | -64.46 | -48.71 |
| 5-year avg ROE %i | -76.93 | -70.33 | -73.61 | -73.37 | -53.49 | -43.45 | -46.48 | -49.36 |
| EBIT margin %i | -435.81 | -354.68 | -665.26 | -2,201.30 | 124,855.88 | -20,753.99 | -475,250.00 | -212,531.71 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.70 | 10.04 | 19.16 | 11.17 | 11.31 | 17.26 | 13.11 | 18.55 |
| Quick ratioi | 8.44 | 9.91 | 18.99 | 10.73 | 10.99 | 16.69 | 12.90 | 18.35 |
| Debt / assetsi | 1.05 | 3.23 | 0.74 | 0.70 | 0.54 | 0.32 | 1.21 | 12.75 |
| LT debt / equityi | 1.04 | 3.26 | 0.65 | 0.56 | 0.36 | 0.09 | 1.14 | 15.76 |
| Interest coveragei | -151.55 | -9,169.51 | -5,779.86 | -17,164.99 | -10,612.75 | -2,526.06 | -10,561.11 | -53.26 |
| Revenue CAGR (3Y) %i | -0.98 | 141.85 | -8.65 | -24.71 | -- | -62.66 | -83.45 | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -57.28 | -55.91 | -52.61 | -50.57 | -42.75 | -28.87 |
| ROA %i | -52.22 | -48.25 | -45.82 | -42.03 | -36.96 | -25.58 |
| ROIC %i | -61.43 | -56.47 | -53.36 | -48.71 | -41.97 | -29.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -454,560.00 | -440,775.00 | -419,175.00 | -212,531.71 | -245,494.44 | -284,593.55 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.85 | 20.44 | 17.18 | 18.55 | 29.56 | 26.78 |
| Quick ratioi | 15.54 | 19.95 | 16.83 | 18.35 | 29.43 | 26.37 |
| Debt / assetsi | 1.01 | 8.33 | 7.28 | 12.75 | 10.68 | 6.83 |
| LT debt / equityi | 0.94 | 9.67 | 8.44 | 15.76 | 12.53 | 7.54 |
| Interest coveragei | -10,101.33 | -324.10 | -110.16 | -53.26 | -32.70 | -24.95 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing novel therapies for serious liver diseases100.00%
Region
United States100.00%
Quote time 2026-10-08 10:00:36 · For reference only, not investment advice and not tailored to your situation.